Targeting different types of small cell lung cancer with new treatments
Official title: Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer
Funded at New York University School of Medicine · NIH-11043435 · Data updated 2026-11-12
This study is looking at new ways to treat small cell lung cancer by testing combinations of treatments that target specific proteins, and it’s for patients who want to explore innovative options to improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $673,898 |
| NIH project number | 5R01CA282437-02 |
| Project ID | NIH-11043435 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with small cell lung cancer, particularly those whose disease has not responded well to standard treatments.
✕Less likely to help
Patients with non-small cell lung cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of lung cancer that often recurs after initial treatment. The study aims to explore new treatment strategies by combining inhibitors that target specific proteins involved in the cancer's growth and survival. By understanding the different subtypes of SCLC and their unique characteristics, the research seeks to develop more effective therapies that could improve patient outcomes. Patients may have the opportunity to participate in trials that test these innovative treatment approaches.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promise in targeting specific pathways in small cell lung cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Wong, Kwok Kin — New York University School of Medicine
- Study coordinator: Wong, Kwok Kin
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.